Clinical development of temsirolimus, a novel mTOR inhibitor, for treatment of advanced malignancies.
Dancey
Janet E
JE
The Ontario Institute for Cancer Research, Toronto, Canada.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends; D018450:Disease Progression; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011494:Protein Kinases / Q000378:metabolism; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; C401859:temsirolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus